13D·WATCH Activist + Insider Intelligence Live feed Blog About Pilot
SCHEDULE 13D Filed 2026-04-23 Event 2026-04-16 Intent: UNCLEAR SEC 0001875620-26-000007 →

Sands Capital Life Sciences Pulse Fund II, L.P. Alamar Biosciences, Inc. ALMR

Stake: 6.30% Shares: 4,230,926 CUSIP: 010911105 Class: Common Stock, par value $0.0001 per share
AI Analyst Brief conf: low
Sands Capital Life Sciences Pulse Fund II files a 13D on ALMR with 4.23M shares, notable because this is the fund's first 13D/G filing and lands on an issuer that has already attracted 2 activist filings in the past 90 days — suggesting ALMR is under coordinated pressure despite no disclosed purpose in this extract.

Item 4 — Purpose of Transaction

The Reporting Persons acquired and hold the Common Stock for investment purposes in the ordinary course of Sands Pulse Fund II's investment activities. Subject to applicable legal requirements or contractual restrictions, one or more of the Reporting Persons may purchase additional securities of the Issuer from time to time in open market or private transactions depending on their evaluation of the Issuer's business, prospects and financial condition, the market for the Issuer's securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Persons' ownership of the Issuer's securities, other opportunities available to the Reporting Persons, and general economic, money market and stock market conditions. In addition, depending upon the factors referred to above, the Reporting Persons may dispose of all or a portion of their securities of the Issuer at any time. Each of the Reporting Persons reserves the right to increase or decrease its holdings on such terms and at such times as each may decide. In addition, consistent with their investment purpose, the Reporting Persons may engage in communications with persons associated with the Issuer, including shareholders of the Issuer, officers of the Issuer and/or members of the board of directors of the Issuer, to discuss matters regarding the Issuer including but not limited to its operations and strategic direction. Ian Ratcliffe, who serves on the Issuer's board of directors, is an Executive Managing Partner of the Life Sciences Pulse strategy and an Executive Managing Director of Sands Capital Alternatives, and therefore will engage in regular discussions with the Issuer's board of directors and management as part of his duties as a director. Except as set forth in this Schedule 13D, the Reporting Persons do not currently have any plans or proposals that relate to or would result in any of the matters described in paragraphs (a) through (j) of Item 4 of Schedule 13D, although the Reporting Persons reserve the right to formulate such plans or proposals in the future.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
2 13D/G filings on this issuer
1 other filing besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest
Not in latest FINRA snapshot

Other 13D/G Filings on Alamar Biosciences, Inc.

FiledFormFilerStakeShares
2026-04-23 SCHEDULE 13D Illumina Innovation Fund II, L.P. 9.60% 5,856,536 view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →